Formulary guidance and transparency from P&T to point of care


Reality Check on Multiple Sclerosis

Market access for multiple sclerosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: More than half of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions on multiple sclerosis medications 
  • Class Trends: The FDA granted tentative approval for Banner Life Sciences LLC's Bafiertam for the treatment of patients with relapsing forms of multiple sclerosis
  • Key Findings: Contracting is prevalent among interferons, where formulary preference drives choice

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.